$13.32+0.25 (+1.91%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Burning Rock Biotech (BNR) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
5 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue compounds ~−0.8%/yr (FY21→FY25), net margin −10.3%.
The lines that matter · FY21–FY25
Revenue ($M)▲9.2%
77.2
FY21→FY25CAGR −0.8%/yr
Net income ($M)▲83.3%
−7.9
FY21→FY25CAGR —
Free cash flow ($M)▲64.0%
−4.8
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+2.0%
104.2mn → 106.3mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$750.6K
steady at 1.0% of revenue (+1.1% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-10¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 71.7% → 74.7%. Net margin -10.3% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 77,157.2 | 77,157.2 | 70,667.3 | 75,696.1 | 81,661.8 | 79,694.6 | ▲9.2% | −0.8% |
Cost of revenue | 19,541.3 | 19,541.3 | 21,018.7 | 24,536.7 | 26,561.4 | 22,552.2 | ▼7.0% | −3.5% |
Gross profit | 57,615.9 | 57,615.9 | 49,648.6 | 51,159.5 | 55,100.5 | 57,142.5 | ▲16.0% | +0.2% |
Research & development | 23,808.3 | 23,808.3 | 31,823.6 | 48,876.2 | 61,165.1 | 57,724.9 | ▼25.2% | −19.9% |
Selling, general & admin | 18,030.6 | 18,030.6 | 35,844.3 | 61,665.8 | 82,393.4 | 76,931.9 | ▼49.7% | −30.4% |
Total operating expenses | 65,458.7 | 65,458.7 | 98,634.0 | 145,431.3 | 197,246.1 | 182,219.2 | ▼33.6% | −22.6% |
Operating incomefeeds ROC rank | −7,842.7 | −7,842.7 | −48,985.4 | −94,271.9 | −142,145.7 | −125,076.7 | ▲84.0% | — |
Other income, net | 150.9 | 150.9 | 2,304.1 | 2,538.1 | 1,617.9 | 198.7 | — | — |
Pretax income | −7,691.9 | −7,691.9 | −46,681.3 | −91,733.8 | −140,527.8 | −124,878.1 | ▲83.5% | — |
Income tax | 222.5 | 222.5 | 806.2 | 336.3 | 287.8 | 141.1 | ▼72.4% | +12.1% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −7,914.4 | −7,914.4 | −47,487.6 | −92,070.2 | −140,815.5 | −125,019.1 | ▲83.3% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | —A | —A | —A | —A | —A | — | — |
Diluted shares (mn) | 106.30 | 106.30 | 102.94 | 102.40 | 103.91 | 104.21 | ▲3.3% | +0.5% |
| Margins | ||||||||
Gross margin68th pct in Healthcare | 74.7% | 74.7% | 70.3% | 67.6% | 67.5% | 71.7% | ▲4.4pp | +3.0pp |
Operating margin | −10.2% | −10.2% | −69.3% | −124.5% | −174.1% | −156.9% | ▲59.2pp | +146.8pp |
Net margin27th pct in Healthcare | −10.3% | −10.3% | −67.2% | −121.6% | −172.4% | −156.9% | ▲56.9pp | +146.6pp |
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.A Withheld by our checks.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-04-28 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Burning Rock Biotech's revenue last fiscal year?
Burning Rock Biotech reported revenue of $77.2M in fiscal 2025, up 9.2% from fiscal 2024.
What was Burning Rock Biotech's net income?
Burning Rock Biotech reported net income of −$7.9M in fiscal 2025, a net margin of −10.3%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

